Overview

CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Status:
Not yet recruiting

Trial end date:
2026-12-01

Target enrollment:
0

Participant gender:
All

Summary

Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis and are not recommended to receive adjuvant chemotherapy after radical surgery. With the advances in liquid biopsy technology, detection of circulating tumor DNA (ctDNA) can effectively identify early-stage cancer patients with minimal residual disease (MRD) after surgery. According to the growing number of MRD studies in solid tumor, colorectal cancer patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse within two years. This study aims to assess the efficacy of adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPEOX) compared with conventional observation in MRD-positive patients with stage I colorectal cancer and clinically low-risk stage II colon cancer.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Zhejiang University

Collaborator:

GeneCast Biotechnology Co., Ltd.

Treatments:

Capecitabine
Oxaliplatin

Criteria

Inclusion Criteria:

1. Colorectal cancer confirmed by pathology, and the TNM stage (AJCC v8) is stage I or
stage II. Stage II patients have T3 colonic adenocarcinoma with proficient
mismatch-repair system (by immunohistochemistry for four mismatch repair proteins
MSH1, MSH2, MSH6, and PMS2) and have no the following clinical risk factors: a) less
than 12 lymph nodes examined; b) mucinous carcinoma; c) poor differentiation; d) bowel
obstruction or perforation; e) lymphatic/vascular invasion, perineural invasion; f)
close, indeterminate, uncertain, positive margins

2. ECOG performance status 0-1

3. No neoadjuvant therapy before surgery

4. Appropriate for active surveillance (i.e., no adjuvant chemotherapy) based on current
practice patterns or according to the Chinese Society of Clinical Oncology guidelines
for Colorectal Cancer (version 2022)

5. No history of other primary cancers in the past 3 years

6. No history of bone marrow, stem cell or organ transplant

7. Blood samples from 7 to 21 days after surgery were tested positive for ctDNA (tested
by MinerVa MRD assay)

8. Pregnancy test done within 14 days before randomization must be negative (for women of
childbearing potential only)

9. Voluntarily join the study and sign the informed consent document

10. No unstable or any medical condition that affects patient safety and study compliance
evaluated by researchers

11. Availability and provision of adequate surgical tumor tissue for molecular diagnostics

Exclusion Criteria:

1. Patients with multiple primary colorectal cancers

2. Patients with another primary cancer

3. Patients have the following conditions by blood test, or have obvious contraindication
in adjuvant chemotherapy:

1. Moderate/severe renal impairment (GFR<30 ml/min), as calculated by the Cockcroft
and Gault equation

2. Absolute neutrophil count <1.5×109/L

3. Platelet count < 75×109/L

4. Hemoglobin <90 g/L

5. Aspartate aminotransferase/Alanine aminotransferase >2.5 × upper limit of normal

4. Lactating women

5. Have serious or uncontrolled medical condition that may preclude compliance with the
protocol